Castle Biosciences (CSTL) Change in Acquisitions & Divestments (2023 - 2026)

Castle Biosciences has reported Change in Acquisitions & Divestments for 4 years, with the latest figure at $41.0 million in Q2 2026.

• Quarterly Change in Acquisitions & Divestments fell 6.82% year-over-year to $41.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $189.0 million (up 6.33% YoY) and the FY2025 annual result came in at $189.2 million, up 2.88% from the prior year.
• Change in Acquisitions & Divestments advanced to $41.0 million in Q2 2026 per CSTL's latest filing, from $39.1 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $60.6 million in Q4 2024 and troughed at $36.2 million in Q2 2024.
• A 4-year average of $45.7 million and a median of $44.5 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The widest YoY moves for Change in Acquisitions & Divestments: up 49.18% in 2025, down 27.69% in 2025.
• Over 4 years, Change in Acquisitions & Divestments stood at $48.5 million in 2023, then gained by 25.05% to $60.6 million in 2024, then decreased by 10.96% to $54.0 million in 2025, then decreased by 24.07% to $41.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $41.0 million, $39.1 million, and $54.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.